130
Participants
Start Date
December 6, 2024
Primary Completion Date
December 31, 2028
Study Completion Date
December 31, 2028
JNJ-90301900
JNJ-90301900 will be injected intratumorally and/or intranodally.
Durvalumab
Durvalumab will be administered as intravenous (IV) infusion as cIT.
Concurrent Chemo/Radiation Therapy (cCRT)
Radiation by intensity modulated radiation therapy (IMRT) will be administered.
Concurrent Chemo/Radiation Therapy (cCRT): Carboplatin
Carboplatin will be administered as IV infusion as platinum-based doublet chemotherapy.
Concurrent Chemo/Radiation Therapy (cCRT): Paclitaxel
Paclitaxel will be administered as IV infusion as platinum-based doublet chemotherapy.
RECRUITING
Macquarie University, North Ryde
RECRUITING
Royal Melbourne Hospital, Parkville
RECRUITING
NYU Langone Health, New York
RECRUITING
Memorial Sloan Kettering Cancer Center, New York
RECRUITING
Hopital Nord Marseille, Marseille
RECRUITING
Hosp. Clinico Univ. de Santiago, Santiago de Compostela
RECRUITING
University of Pennsylvania, Philadelphia
RECRUITING
University of North Carolina at Chapel Hill, Chapel Hill
RECRUITING
Hosp. Univ. 12 de Octubre, Madrid
RECRUITING
FirstHealth of the Carolinas, Pinehurst
RECRUITING
Hopital De La Cavale Blanche, Brest
RECRUITING
Emory University Winship Cancer Institute, Atlanta
RECRUITING
Clinica Univ. de Navarra, Pamplona
RECRUITING
Orlando Health Cancer Institute, Orlando
RECRUITING
Hosp. Univ. I Politecni La Fe, Valencia
RECRUITING
Sakarya University Training and Research Hospital, Sakarya
RECRUITING
Hopital Tenon, Paris
RECRUITING
MD Anderson Cancer Center, Houston
RECRUITING
University of Connecticut Health Center, Farmington
RECRUITING
University of Vermont Medical Center, Burlington
RECRUITING
Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein, São Paulo
RECRUITING
Prince of Wales Hospital, Shatin
RECRUITING
Radboud Umcn, Nijmegen
Johnson & Johnson Enterprise Innovation Inc.
INDUSTRY